Overview
Genetic central nervous system (CNS) malformation is a broad grouping term used in Orphanet (ORPHA:183506) to classify a heterogeneous collection of rare congenital structural abnormalities of the brain and/or spinal cord that arise due to underlying genetic causes. These malformations result from disruptions in the complex processes of neural tube closure, neuronal proliferation, neuronal migration, cortical organization, or cerebellar and brainstem development. They encompass a wide spectrum of conditions including, but not limited to, holoprosencephaly, lissencephaly, polymicrogyria, schizencephaly, corpus callosum agenesis, cerebellar malformations, and various forms of neural tube defects with a genetic basis. Clinical features vary considerably depending on the specific malformation but commonly include intellectual disability, developmental delay, seizures or epilepsy, motor impairment (including spasticity and hypotonia), microcephaly or macrocephaly, and in some cases hydrocephalus. Cranial nerve dysfunction, visual impairment, and feeding difficulties may also be present. The severity ranges from mild learning difficulties to profound neurological disability incompatible with independent life. Because this is a classification category rather than a single disease entity, the underlying genetic causes are extremely diverse, involving numerous genes and inheritance patterns including autosomal dominant, autosomal recessive, X-linked, and de novo mutations. Treatment is largely supportive and symptomatic, including antiepileptic medications for seizure management, physical and occupational therapy, surgical interventions for hydrocephalus (such as ventriculoperitoneal shunting), and multidisciplinary rehabilitation. Genetic counseling is recommended for affected families. No curative therapies currently exist for most genetic CNS malformations.
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventNoema Pharma AG — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Genetic central nervous system malformation.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Genetic central nervous system malformation at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Genetic central nervous system malformation.
Community
No community posts yet. Be the first to share your experience with Genetic central nervous system malformation.
Start the conversation →Latest news about Genetic central nervous system malformation
No recent news articles for Genetic central nervous system malformation.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Genetic central nervous system malformation
What is Genetic central nervous system malformation?
Genetic central nervous system (CNS) malformation is a broad grouping term used in Orphanet (ORPHA:183506) to classify a heterogeneous collection of rare congenital structural abnormalities of the brain and/or spinal cord that arise due to underlying genetic causes. These malformations result from disruptions in the complex processes of neural tube closure, neuronal proliferation, neuronal migration, cortical organization, or cerebellar and brainstem development. They encompass a wide spectrum of conditions including, but not limited to, holoprosencephaly, lissencephaly, polymicrogyria, schize
At what age does Genetic central nervous system malformation typically begin?
Typical onset of Genetic central nervous system malformation is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Genetic central nervous system malformation?
13 specialists and care centers treating Genetic central nervous system malformation are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.